Folotyn (Pralatrexate) Receives FDA Approval Global Update
Folotyn (generic name: Pralatrexate), the first drug approved by the U.S. Food and Drug Administration…
Articles
Rezivertinib Mesylate Capsules: A New Hope For NSCLC Patients
March 20, 2025 – A breakthrough in cancer treatment has emerged with the approval and…
Tabrecta Approval Offers New Hope For Non-Small Cell Lung Cancer Patients
May 6, 2020- The U.S. Food and Drug Administration (FDA) today approved Tabrecta (capmatinib) for…
Brineura Promises To Prolong Quality Of Life In CLN2 Patients
Brineura® (cerliponase alfa), the only FDA-approved enzyme replacement therapy for late-infantile neuronal ceroid lipofuscinosis type 2…
Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism (SHPT) In Dialysis Patients
Parsabiv (Etelcalcetide), an innovative calcimimetic, was recently formally approved for the treatment of secondary hyperparathyroidism…
Retevmo (Selpercatinib) Achieves Positive Results in Phase III Clinical Trial
August 5, 2023 – Eli Lilly and Company (Eli Lilly) announced that its RET inhibitor…
Isturisa(Osilodrostat): New Hope For Cushing’s Syndrome Treatment
Cushing’s syndrome is a rare disease caused by the overproduction of cortisol from the adrenal…
Actimmune (Interferon Gamma-1b) Gains Expanded Approval For Severe Osteopetrosis In Pediatric Patients
March 29, 2025 – Horizon Therapeutics, the manufacturer of Actimmune® (interferon gamma-1b), has announced that the U.S.…
Augtyro (Repotrectinib) Capsules: What Patients Really Want to Know
If you or a loved one has been prescribed Augtyro Repotrectinib for non-small cell lung…
Lorviqua (Lorlatinib) Approved In EU For First-Line Treatment Of ALK-Positive Non-Small Cell Lung Cancer
Pfizer Inc. recently announced that its third-generation anaplastic lymphoma kinase (ALK) inhibitor Lorviqua (generic name:…